Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Eur J Pharmacol
; 884: 173455, 2020 Oct 05.
Article
in English
| MEDLINE | ID: covidwho-715016
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Protein Binding
/
Coronavirus Infections
/
Peptidyl-Dipeptidase A
/
Virus Internalization
/
Drug Discovery
/
Pandemics
/
Spike Glycoprotein, Coronavirus
/
Betacoronavirus
Limits:
Humans
Language:
English
Journal:
Eur J Pharmacol
Year:
2020
Document Type:
Article
Affiliation country:
J.ejphar.2020.173455
Similar
MEDLINE
...
LILACS
LIS